Research Progress in the Relationship Between Hyperhomocysteinemia and Chronic Kidney Disease.
10.3881/j.issn.1000-503X.16112
- Author:
Cong-Cong DING
1
;
Xiao HUANG
1
;
Hui-Hui BAO
1
;
Xiao-Shu CHENG
1
Author Information
1. Department of Cardiovascular Medicine,The Second Affiliated Hospital of Nanchang University,Nanchang 330006,China.
- Publication Type:Review
- Keywords:
chronic kidney disease;
folic acid;
homocysteine;
hyperhomocysteinemia;
vitamin
- MeSH:
Humans;
Hyperhomocysteinemia/complications*;
Renal Insufficiency, Chronic/complications*
- From:
Acta Academiae Medicinae Sinicae
2025;47(2):281-288
- CountryChina
- Language:English
-
Abstract:
In patients with chronic kidney disease(CKD),the incidence of cardiovascular events and the mortality rate are significantly higher than those in the general population.Approximately 85% of end-stage CKD patients develop hyperhomocysteinemia(HHcy)due to impaired renal function.It is not yet fully determined whether HHcy merely acts as a biomarker of CKD or plays a role in the pathogenesis.Although supplementation with folic acid and other B vitamins(B6 and B12)has been proven to lower the plasma level of total homocysteine,their effectiveness in slowing CKD progression or reducing cardiovascular complications remains uncertain.This article reviews the latest research progress in the relationship between HHcy and CKD,aiming to give new insights into the prevention and treatment of CKD and its complications.
